Insmed’s (INSM) Overweight Rating Reaffirmed at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their overweight rating on shares of Insmed (NASDAQ:INSM – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company’s stock. Several other equities analysts also recently issued reports on INSM. Evercore ISI upped their price […]

Leave a Reply

Your email address will not be published.

Previous post Morgan Stanley Trims Enphase Energy (NASDAQ:ENPH) Target Price to $94.00
Next post L.B. Foster (NASDAQ:FSTR) Upgraded to Strong-Buy at